ES2699099T3 - Derivados de tamoxifeno para el tratamiento de enfermedades neoplásicas, especialmente con alto nivel de proteína HER2 - Google Patents

Derivados de tamoxifeno para el tratamiento de enfermedades neoplásicas, especialmente con alto nivel de proteína HER2 Download PDF

Info

Publication number
ES2699099T3
ES2699099T3 ES14721738T ES14721738T ES2699099T3 ES 2699099 T3 ES2699099 T3 ES 2699099T3 ES 14721738 T ES14721738 T ES 14721738T ES 14721738 T ES14721738 T ES 14721738T ES 2699099 T3 ES2699099 T3 ES 2699099T3
Authority
ES
Spain
Prior art keywords
general formula
tamoxifen
triphenylphosphonium
her2
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14721738T
Other languages
English (en)
Spanish (es)
Inventor
Jirí Neuzil
Jan Stursa
Lukás Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Springtide Ventures S R O
BIOTECHNOLOGICKY USTAV AV CR V V I
Smart Brain sro
Original Assignee
Springtide Ventures S R O
BIOTECHNOLOGICKY USTAV AV CR V V I
Smart Brain sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2699099(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Springtide Ventures S R O, BIOTECHNOLOGICKY USTAV AV CR V V I, Smart Brain sro filed Critical Springtide Ventures S R O
Application granted granted Critical
Publication of ES2699099T3 publication Critical patent/ES2699099T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
ES14721738T 2013-04-24 2014-04-07 Derivados de tamoxifeno para el tratamiento de enfermedades neoplásicas, especialmente con alto nivel de proteína HER2 Active ES2699099T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (1)

Publication Number Publication Date
ES2699099T3 true ES2699099T3 (es) 2019-02-07

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14721738T Active ES2699099T3 (es) 2013-04-24 2014-04-07 Derivados de tamoxifeno para el tratamiento de enfermedades neoplásicas, especialmente con alto nivel de proteína HER2

Country Status (21)

Country Link
US (1) US9896466B2 (cg-RX-API-DMAC10.html)
EP (1) EP2989110B1 (cg-RX-API-DMAC10.html)
JP (1) JP6375091B2 (cg-RX-API-DMAC10.html)
KR (1) KR101764991B1 (cg-RX-API-DMAC10.html)
CN (1) CN105452265B (cg-RX-API-DMAC10.html)
AU (1) AU2014256546B2 (cg-RX-API-DMAC10.html)
CA (1) CA2909994C (cg-RX-API-DMAC10.html)
CY (1) CY1120821T1 (cg-RX-API-DMAC10.html)
DK (1) DK2989110T3 (cg-RX-API-DMAC10.html)
EA (1) EA029881B1 (cg-RX-API-DMAC10.html)
ES (1) ES2699099T3 (cg-RX-API-DMAC10.html)
GE (2) GEAP201813996A (cg-RX-API-DMAC10.html)
HR (1) HRP20181872T1 (cg-RX-API-DMAC10.html)
HU (1) HUE042239T2 (cg-RX-API-DMAC10.html)
MD (1) MD4626C1 (cg-RX-API-DMAC10.html)
NZ (1) NZ713589A (cg-RX-API-DMAC10.html)
PL (1) PL2989110T3 (cg-RX-API-DMAC10.html)
PT (1) PT2989110T (cg-RX-API-DMAC10.html)
SI (1) SI2989110T1 (cg-RX-API-DMAC10.html)
UA (1) UA116469C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014173374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548318B2 (en) * 2015-07-03 2020-02-04 Bayer Cropscience Aktiengesellschaft N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action
CN107709317B (zh) * 2015-07-03 2021-05-11 拜耳作物科学股份公司 具有除草作用的n-(1,3,4-噁二唑-2-基)芳基甲酰胺衍生物
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
EP3484463B1 (en) 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2019083997A1 (en) 2017-10-24 2019-05-02 Lunella Biotech, Inc. MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING
CR20200238A (es) 2017-11-24 2020-12-04 Lunella Biotech Inc Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20220211728A1 (en) * 2019-04-16 2022-07-07 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE130293T1 (de) * 1990-10-01 1995-12-15 Univ Texas Tamoxifenderivate mit hoher affinität und ihre verwendung.
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
AU2005261654A1 (en) * 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
KR101642157B1 (ko) * 2008-03-14 2016-07-22 스티븐 존 랄프 미토콘드리아로 전달되는 항암 화합물
WO2010121177A2 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
NZ713589A (en) 2017-12-22
PL2989110T3 (pl) 2019-03-29
AU2014256546A1 (en) 2015-11-12
EA029881B1 (ru) 2018-05-31
HRP20181872T1 (hr) 2019-02-08
CN105452265B (zh) 2017-05-10
GEAP201813996A (en) 2018-03-12
MD20150117A2 (ro) 2016-08-31
CY1120821T1 (el) 2019-12-11
EP2989110A1 (en) 2016-03-02
KR101764991B1 (ko) 2017-08-10
CN105452265A (zh) 2016-03-30
EA201591918A1 (ru) 2016-02-29
US20160075726A1 (en) 2016-03-17
HK1216317A1 (zh) 2016-11-04
EP2989110B1 (en) 2018-08-08
KR20150144756A (ko) 2015-12-28
SI2989110T1 (sl) 2019-01-31
MD4626C1 (ro) 2019-11-30
JP2016522179A (ja) 2016-07-28
GEP20186868B (en) 2018-06-25
PT2989110T (pt) 2018-11-15
DK2989110T3 (en) 2018-12-03
CA2909994A1 (en) 2014-10-30
US9896466B2 (en) 2018-02-20
JP6375091B2 (ja) 2018-08-15
WO2014173374A1 (en) 2014-10-30
AU2014256546B2 (en) 2017-03-30
HUE042239T2 (hu) 2019-06-28
MD4626B1 (ro) 2019-04-30
UA116469C2 (uk) 2018-03-26
CA2909994C (en) 2018-06-26

Similar Documents

Publication Publication Date Title
AU2014256546B2 (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
Huang et al. Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt (IV) moiety with a unique mode of action
Yi et al. Synthesis, characterization and anticancer activity in vitro and in vivo evaluation of an iridium (III) polypyridyl complex
JP2016522179A5 (cg-RX-API-DMAC10.html)
Li et al. Pt (IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance
Štarha et al. Platinum (II) iodido complexes of 7-azaindoles with significant antiproliferative effects: an old story revisited with unexpected outcomes
Nadar et al. Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity
Du et al. Design, synthesis and biological evaluation of iridium (III) complexes as potential antitumor agents
Yang et al. A novel drug prejudice scaffold-imidazopyridine-conjugate can promote cell death in a colorectal cancer model by binding to β-catenin and suppressing the Wnt signaling pathway
Shan et al. First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway
Mohassab et al. Design and synthesis of new quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
Shao et al. Design of a prodrug photocage for cancer cells detection and anticancer drug release
CA3045365C (en) Compounds for treatment of senescence-related disorders
WO2019131998A1 (ja) アスタチン溶液及びその製造方法
Usman et al. A novel biocompatible formate bridged 1D-Cu (ii) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells
CZ304553B6 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
ES2608781T3 (es) Compuestos 3,4-bis(catecol)pirrol-N-sustituidos, su preparación y su utilización en el tratamiento del cáncer
Liu et al. A novel cinnamic acid derivative for hepatocellular carcinoma therapy by degrading METTL16 protein
CZ201466A3 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
US10577387B1 (en) Platinum (II) complexes containing N-heterocyclic carbene ligand and pincer ligands, synthesis, and their applications in cancer treatment
Andreeva et al. In vitro cytotoxicity evaluation of triphenylphosphonium (TPP) conjugates of some acetylenated nucleic bases and their analogues
Fernandes Synthesis and Evaluation of New Boronated Cytotoxic Platforms
WO2024102946A2 (en) Boron-based enolase ligands and methods of use for treatment of cancer